RMS: Medovex Corporation Announces Definitive Agreement to Acquire the Pulmonary Biomedical Services and Patient Delivery Platform of Regenerative Medicine Solutions, LLC

ALPHARETTA, Ga., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Medovex Corporation (OTCQB:MDVX) ("Medovex") announced today that it has signed a definitive agreement to acquire the pulmonary biomedical services and patient delivery platform of Regenerative Medicine Solutions, LLC, ("RMS") in an all-stock transaction. Regenerative Medicine SolutionsRMS is a Tampa, Florida-based biomedical services company that manages Lung Health Institute, a leader in regenerative medicine specializing in cellular therapies to treat COPD and other chronic lung disorders.William "Bill" Horne, Medovex's newly appointed CEO and a founder and former CEO of Laser Spine Institute ("LSI") stated, "This transaction embodies our commitment to acquire and develop a diversified portfolio of innovative and disruptive healthcare solutions. The footprint that RMS has helped create allows us to immediately expand services strategically throughout the United States and position Medovex for accelerated growth." The RMS asset purchase reunites Horne's former LSI executive management team, largely responsible for its emergence as the market leader in minimally invasive spine surgery. RMS provides management services to all five of the Lung Health Institute clinics, which have treated more than 6,000 patients. As reported in the journal, Stem Cell & Regenerative Medicine, data shows that the Lung Health Institute clinics cellular therapy protocols resulted in statistically significant outcomes, improving the quality of life of 73% of COPD patients three months after treatment. In December 2017, the five clinics were among the first cellular therapy providers to earn ambulatory health care accreditation by The Joint Commission, which is widely ...Full story available on Benzinga.com